SCHEMBL4882893

SCHEMBL4882893

Cc1ccc(CNC(=O)c2ccc3ncnc(Nc4ccc(N5CCOCC5)cc4)c3c2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.57
MAPK1 P28482 3/20 0.57
HTT P42858 3/20 0.57
AHR P35869 1/20 0.57
PI4KB Q9UBF8 1/20 0.53
BRAF P15056 2/20 0.50
EGFR P00533 1/20 0.50
KDR P35968 1/20 0.50
KDM1A O60341 1/20 0.49
HDAC1 Q13547 1/20 0.49
ERBB2 P04626 1/20 0.49
GAA P10253 4/20 0.49
LMNA P02545 3/20 0.49
L3MBTL1 Q9Y468 3/20 0.49
MC4R P32245 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
CLK1 P49759 1/20 0.49
GSK3A P49840 1/20 0.49
GSK3B P49841 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4890691 0.91 MAPT (0.55) MAPTMAPK1HTTAHRPI4KB
SCHEMBL4891765 0.87 MAPT (0.63) MAPTMAPK1HTTAHRPI4KB
SCHEMBL4884655 0.85 STAT6 (0.54) MAPTMAPK1HTTAHRPI4KB
SCHEMBL4888741 0.84 MAPT (0.67) MAPTMAPK1HTTAHRPI4KB
SCHEMBL4890194 0.81 MAPT (0.71) MAPTMAPK1HTTAHRPI4KB
SCHEMBL14026144 0.81 MAPT (0.77) MAPTMAPK1HTTAHRPI4KB
SCHEMBL4888073 0.80 MAPK1 (0.66) MAPTMAPK1HTTAHRPI4KB
SCHEMBL4884795 0.77 MAPT (0.61) MAPTMAPK1HTTAHREGFR
SCHEMBL4008515 0.75 MAPT (0.80) MAPTMAPK1HTTAHRPI4KB
SCHEMBL4007231 0.74 MAPT (0.78) MAPTMAPK1HTTAHRPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents ARROW THERAPEUTICS LIMITED (GB) 2008-12-18 US disclosed
EP-1748991-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS Arrow Therapeutics Limited (GB) 2007-02-07 EP disclosed
WO-2005105761-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS ARROW THERAPEUTICS LIMITED (GB) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents EIF2AK2, MAVS, IRF3 MAPT 2064/4885MAPK1 1945/4885HTT 3581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.